AT9283
| Title | Journal |
|---|---|
| AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. | International journal of cancer 20120615 |
| A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. | Annals of oncology : official journal of the European Society for Medical Oncology 20120501 |
| Effects of the novel aurora kinase/JAK inhibitor, AT9283 and imatinib on Philadelphia positive cells in vitro. | Blood cells, molecules & diseases 20120315 |
| Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia. | Leukemia research 20110901 |
| Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. | Clinical cancer research : an official journal of the American Association for Cancer Research 20110515 |
| AT-9283, a small-molecule multi-targeted kinase inhibitor for the potential treatment of cancer. | Current opinion in investigational drugs (London, England : 2000) 20101201 |
| Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells. | Blood 20100923 |
| AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders. | British journal of haematology 20100701 |
| Aurora kinase inhibitors as anti-cancer therapy. | Anti-cancer drugs 20100401 |
| Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283. | Cell cycle (Georgetown, Tex.) 20090615 |
| Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. | Journal of medicinal chemistry 20090122 |